Page 1

Follo form:	w-up form is submitted t s can be submitted to the	o the BCR. However, if the patient has compl BCR at the time the Enrollment form is subr	
Quest	tions regarding this form	should be directed to Nationwide Children's	s Hospital (NCH) or OCG.
lissu	e Source Site (TSS):	TSS Identifier:	TSS Unique Patient Identifier:
Comp	leted By (Interviewer Name	on OpenClinica):	Completed Date:
#	Data Element	Entry Alternatives	Working Instructions
1*	Indication of Regimen	 Initial Adjuvant Progression after initial Recurrence Palliative Unknown 	Text term to identify the reason for the administration of a treatment regimen. 5102381
2*	Lymphoma Treatment Type	 Chemotherapy Radiation Stem Cell Transplant Surgery No Treatment Other Treatment 	Text term that describes the kind of treatment that was given for the primary lymphoma. 5544691
3	Other Lymphoma Treatment Type		Indicate the other treatment type for the lymphoma. 2861111
4†	Other Treatment Start Date	///	Provide the date that therapy was started. 3103072 (month), 3103070 (day), 3103074 (year)
5†	Other Treatment End Date	$\frac{1}{(\text{month})} / \frac{1}{(\text{day})} / \frac{1}{(\text{year})} $	Provide the date that therapy was completed/ ended. 3103080 (month), 3103078 (day), 31030782 (year)
Chen	notherapy <mark>(please answer follo</mark> v	wing questions only if Chemotherapy was selected above	
6†	Chemotherapy Start Date	(month) (day) (year)	Date chemotherapy regimen started. 2897050 (month), 2897052 (day), 2897054 (year)
7	Did chemotherapy end during this reporting period?	□ Yes □ No	Indicate whether chemotherapy administration ended during this reporting period. 2188260
8†	Chemotherapy End Date	(month) (day) (year)	Date chemotherapy regimen ended. 2897056 (month), 2897058 (day), 2897060 (year)
9†	Pharmaceutical Regimen	 BACOP BACOP C-MOPP CAP-BOP CHOP + Bleomycin CHOP + Etoposide CHOP-14 CHOP-14 + Rituximab CHOP-21 CHOP-21 + Rituximab CNOP CODOX + Rituximab CVP DA-EPOCH DA-EPOCH + Rituxumab F-MACHOP High Dose Methotrexate w/Leucovorin HyperCVAD-Mtx/AraC + Rituximab ICE ICE + Rituxumab LNH-84 LNH-87 M-BACOP MACOP-B 	Text term or code to represent the name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma. 3366758

Page 2

Treatment Supplemental Form

V1.02 050117

#	Data Element	Entry Alternatives		Working Instructions
	2000 2001010	□ ProMace-CytaBOM		
		□ ProMace-MOPP		
		 VACOP-B Vanderbilt regimen + Ritu 	wimah	
		□ Single Agent Therapy (ple	ease specify)	
		□ Other Pharmaceutical Reg		
		🗆 Unknown		m
				Text term or abbreviation to represent another name of a pharmaceutical regimen containing two or more agents which
10	If Other Pharmaceutical			are given together or separately to treat a patient with
10	Regimen, specify			malignant lymphoma that was not already mentioned or
				specified. 3366930
				Text name for agent used without other agents in a treatment
11	If Single-Agent Therapy,			regimen or study.
	specify			3590022
				The total number of cycles administered to the patient of a
12	Number of Cycles			protocol specified drug or therapy agent as of the current
				report. 62590
Radi	ation Therapy <mark>(please answer f</mark>	ollowing questions only if Radio	ation was selected in the tre	
13†	Radiation Therapy Start	// .		Date radiation therapy started.
13.	Date	(month) (day)	(year)	2897100 (month), 2897102 (day), 2897104 (year)
	Did radiation therapy end	□ Yes		Indicate whether radiation therapy ended during this reporting period.
14	during this reporting	□ No		4618471
	period?			
15†	Radiation Therapy End	(month) (day)	(waan)	Date radiation therapy ended. 2897106 (month), 2897108 (day), 2897110 (year)
	Date	(month) (day)	(year)	A numeric value for the total dose volume of radiation therapy
16	Total Dose of Radiation	(Gy))	given to a patient, in Gray.
	Therapy			36
			□ Leg □ Lung	Text term to identify anatomically-specified areas or fields that are targeted for radiation therapy.
			Lymph node, distant	2416537
			(specify site)	
			Lymph node, locoregional (specify site)	
			Lymph Nodes	
			□ Mantle	
			Mediastinum	
		,	Parametrium	
			 Pelvis Shoulder 	
17†	Radiation Field, extranodal		Skin, lower extremity,	
	extranodal	Intestine	local	
			Skin, total Skin, trunk, local	
			Skin, upper extremity,	
		Pancreas	local	
			□ Spine	
			Supraclavicular Thorax	
		,	Trunk	
		Genitourinary, NOS		
			Other	
			 Unknown Mesenteric 	Identify lymph node sites targeted for radiation therapy.
			Mesenteric Occipital	3762198
	N. d. D. et al. Transford		Paraaortic	
			Parotid	
18	Nodal Regions Targeted		 Popliteal Retroperitoneal 	
			Splenic	
		Inguinal	Submandibular	
		Mediastinal	Supraclavicular	
19	Other Region Targeted			Specify other field of radiation 62999
19	other negion rangeteu			

Page 3

#	Data Element	Entry Alternatives	Working Instructions				
Stem Cell Transplantation (please answer following questions only if Stem Cell Transplantation was selected in the treatment type question above)							
20	Type of Stem Cell Transplantation	 Autologous Syngeneic/Allogeneic related donor Allogeneic, unrelated donor 	Indicate the hematopoietic stem cell source type. 2957417				
21†	Date of Stem Cell Transplantation	(month) (day) (year)	Indicate the date of the hematopoietic stem cell transplant. 3366911 (month), 3366912 (day), 3366913 (year)				
Surgery (please answer following questions only if Surgery was selected in the treatment type question above)							
22†	Date of cancer debulking surgery	(month) (day) (year)	Indicate the date of the the procedure of surgically removing as much of the tumor as possible. 4631583 (month), 4631581(day), 4631584 (year)				
23*	Measure of Best Response of Treatment	 Complete Response Partial Response Stable Disease Progressive Disease Not Applicable (Therapy Ongoing) Unknown 	Indicate the patient's outcome (response) at the end of this treatment regimen. 2857291				

Principal Investigator or Designee Signature

Print Name

_/ ____ / ____ ____ Date